OUP, Celgene and Astellas Venture Management all supplied a portion of the funding to bring the Caltech-founded cancer drug developer's lifetime funding to $92m.

Cleave Therapeutics, a US-headquartered developer of cancer and neurodegenerative disease drugs based on California Institute of Technology (Caltech) research, closed a $12m series B2 round featuring spinout-focused investment firm Osage University Partners (OUP) on Tuesday. Venture capital firm 5AM Ventures led the round, investing together with pharmaceutical firms Celgene and Astellas, the latter through its…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.